Drug Farm completed the first closing of a $55 million Series D financing to advance its clinical and preclinical pipeline.
- Amount
- $55M
- Stage
- Series D
- Announced
- 13 July 2026
- Leads
- Shanghai Pudong Leading Area Investment Center, Shanghai Puxing Collaborative Private Equity Fund Partnership Enterprise
- Other investors
- Tukar Capital, Fuzhou Xinhe Fund, Shenzhen Luohu Donghai Chempartner Investment Fund, Keyuan Pharma, BioVeda China Fund (BVCF), YD Capital, Jiashan State VC, Detong Capital, Wedo Capital, Biometas
- Use of funds
- Advance clinical and preclinical pipeline, accelerate global clinical development, strength
- Checked
- Amount and date checked against the press source